RESUMO
BACKGROUND: Suicide is a major public health concern and a leading cause of death both globally and in the United States. Health-care systems and accreditation bodies, such as The Joint Commission (TJC), have placed growing emphasis on the importance of screening for suicide risk in health-care settings. Providers and administrators interested in implementing screening programs must choose from a number of existing validated screening tools. These tools vary in terms of their ease of use, the age range of their target population, as well as the quality of data supporting their use. OBJECTIVE: Here, we review and summarize the properties of brief suicide risk-screening tools described in the literature and discuss the benefits of using these tools for universal screening in the general hospital setting, as well as the significant limitations in their use in the general hospital setting.
Assuntos
Programas de Rastreamento/métodos , Ideação Suicida , Prevenção do Suicídio , Serviço Hospitalar de Emergência , Hospitalização , Humanos , Questionário de Saúde do Paciente , Escalas de Graduação Psiquiátrica , Reprodutibilidade dos Testes , Medição de Risco , Suicídio/estatística & dados numéricos , Inquéritos e QuestionáriosRESUMO
BACKGROUND: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified. OBJECTIVE: In this article, we seek to provide pharmacologic and treatment recommendations specific to delirium in patients with COVID-19. METHODS: We performed a literature search reviewing the neuropsychiatric complications and treatments in prior coronavirus epidemics including Middle Eastern respiratory syndrome and severe acute respiratory syndrome coronaviruses, as well as the emerging literature regarding COVID-19. We also convened a work group of consultation-liaison psychiatrists actively managing patients with COVID-19 in our hospital. Finally, we synthesized these findings to provide preliminary pharmacologic recommendations for treating delirium in these patients. RESULTS: Delirium is frequently found in patients who test positive for COVID-19, even in the absence of respiratory symptoms. There appears to be a higher rate of agitation, myoclonus, abulia, and alogia. No data are currently available on the treatment of delirium in patients with COVID-19. Extrapolating from general delirium treatment, Middle Eastern respiratory syndrome/severe acute respiratory syndrome case reports, and our experience, preliminary recommendations for pharmacologic management have been assembled. CONCLUSIONS: COVID-19 is associated with neuropsychiatric symptoms. Low-potency neuroleptics and alpha-2 adrenergic agents may be especially useful in this setting. Further research into the pathophysiology of COVID-19 will be key in developing more targeted treatment guidelines.
Assuntos
Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico , Antipsicóticos/uso terapêutico , Encefalopatias/fisiopatologia , Infecções por Coronavirus/fisiopatologia , Delírio/tratamento farmacológico , Agonistas de Dopamina/uso terapêutico , Pneumonia Viral/fisiopatologia , Betacoronavirus , Encefalopatias/psicologia , COVID-19 , Depressores do Sistema Nervoso Central/uso terapêutico , Infecções por Coronavirus/psicologia , Delírio/fisiopatologia , Delírio/psicologia , Moduladores GABAérgicos/uso terapêutico , Humanos , Lorazepam/uso terapêutico , Melatonina/uso terapêutico , Pandemias , Pneumonia Viral/psicologia , Guias de Prática Clínica como Assunto , SARS-CoV-2Assuntos
Anemia Perniciosa/diagnóstico , Delusões/etiologia , Parestesia/etiologia , Transtornos Psicóticos/diagnóstico , Vitamina B 12/sangue , Anemia Perniciosa/complicações , Diagnóstico Diferencial , Feminino , Mãos/diagnóstico por imagem , Cabeça/diagnóstico por imagem , Humanos , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Exame Neurológico , Transtornos Psicóticos/complicações , RadiografiaRESUMO
BACKGROUND: In a preliminary trial, we assessed the efficacy of vortioxetine for major depressive disorder (MDD) during the menopausal transition. Secondary outcomes included hot flashes (HFs), anxiety, and cognitive complaints. METHODS: Perimenopausal and early postmenopausal women with MDD (N = 27) received 8 weeks of open-label, flexible-dose treatment with vortioxetine. The Montgomery-Åsberg Depression Rating Scale (MADRS) was the primary outcome measure. Secondary measures included: HF frequency, the Greene Climacteric Scale (GCS), Menopause-Specific Quality of Life Questionnaire (MEN-QOL), Beck Anxiety Inventory (BAI), Cognitive and Physical Functioning Questionnaire (CPFQ), Digit Symbol Substitution Test (DSST), and Cogstate testing. RESULTS: Of the 27 women, 24 (88.8%) were evaluated (≥1 follow-up), and 21 (77.8%) completed the study; 1 discontinued because of adverse effects. The mean MADRS score decreased significantly (P = .0001) from 31.3 (standard deviation [SD] = 5.5) at pretreatment to 8.1 (SD = 7.8) at posttreatment. The depression response rate (≥50% reduction in MADRS) and remission rate (final MADRS ≤10) were 75% and 70.8%, respectively. GCS, MEN-QOL, BAI, CPFQ, and DSST scores improved significantly (P = .0030, P = .0001, P = .0001, P = .0001, and P = .0133, respectively); Cogstate test scores did not. Frequency and severity of HFs improved significantly (P = .0291 and P = .0299, respectively). CONCLUSIONS: These data support further study of vortioxetine for treating menopausal depression and associated symptoms.
Assuntos
Cognição/efeitos dos fármacos , Transtorno Depressivo Maior/tratamento farmacológico , Menopausa/efeitos dos fármacos , Piperazinas/administração & dosagem , Sulfetos/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Escalas de Graduação Psiquiátrica , Resultado do Tratamento , VortioxetinaRESUMO
INTRODUCTION: Neuropsychiatric manifestations of the coronavirus disease 2019 (COVID-19) have been described, including anosmia, ageusia, headache, paresthesia, encephalitis and encephalopathy. Little is known about the mechanisms by which the virus causes central nervous system (CNS) symptoms, and therefore little guidance is available regarding potential workup or management options. CASES: We present a series of four consecutive cases, seen by our psychiatry consultation service over a one-week period, each of which manifested delirium as a result of infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). DISCUSSION: The four cases highlighted here all occurred in older patients with premorbid evidence of cognitive decline. Unique features seen in multiple cases included rigidity, alogia, abulia, and elevated inflammatory markers. In all four cases, a change in mental status was the presenting symptom, and three of the four cases lacked significant respiratory symptoms. In addition to discussing unique features of the cases, we discuss possible pathophysiologic explanations for COVID-19 delirium. CONCLUSIONS: Delirium should be recognized as a potential feature of infection with SARS-CoV-2 and may be the only presenting symptom. Based on the high rates of delirium demonstrated in prior studies, hospitals should consider adding mental status changes to the list of testing criteria. Further research is needed to determine if delirium in COVID-19 represents a primary encephalopathy heralding invasion of the CNS by the virus, or a secondary encephalopathy related to systemic inflammatory response or other factors.
Assuntos
Encefalopatias/etiologia , Infecções por Coronavirus/complicações , Delírio/etiologia , Pandemias , Pneumonia Viral , Idoso , Idoso de 80 Anos ou mais , Encefalopatias/virologia , COVID-19 , Disfunção Cognitiva/complicações , Infecções por Coronavirus/patologia , Delírio/virologia , Feminino , Humanos , MasculinoRESUMO
Management of bipolar disorder during pregnancy often involves medications with potential adverse effects, including risks to the mother and fetus. Although some specifics are known, many medications continue to have incompletely characterized reproductive safety profiles. Women with bipolar disorder who are planning pregnancy face challenging decisions about their treatment; careful risk-benefit discussions are necessary. With the goal of further informing these discussions, this article reviews the data currently available regarding medication safety in the management of bipolar disorder during pregnancy, with specific attention to lithium, valproic acid, lamotrigine, carbamazepine, and antipsychotic medications.